Mechanisms of protective effects induced by blockade of the renin-angiotensin system: Novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes

Diabetic Medicine

Volumn 24, Issue 2, 2007, Pages 110-116

  Leung, P S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Pancreatic cell dysfunction; Renin angiotensin system; Type 2 diabetes mellitus

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRILAT; IRBESARTAN; LOSARTAN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SARALASIN; TELMISARTAN; VALSARTAN; ZOFENOPRILAT;

ACUTE PANCREATITIS; APOPTOSIS; CELL SECRETION; CLINICAL TRIAL; HEART FAILURE; HUMAN; HYPERTENSION; INNER CELL MASS; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; PANCREAS BLOOD FLOW; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UPREGULATION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; ISLETS OF LANGERHANS; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTOR AGENTS;

EID: 33846576694     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02072.x     Document Type: Review

References (63)

1. Wyatt HR. The prevalence of obesity. Prim Care 2003; 30: 267-279.
2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001; 344: 1343-1350.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
4. Diamond J. The double puzzle of diabetes. Nature 2003; 423: 599-602.
5. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Diabetes Metab 2004; 30: 487-496.
6. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: overview of physiological and biochemical mechanisms. Diabetes Metab 2004; 30: 498-505.
7. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248.
8. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects of islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-133.
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004; 28: 1047-1053.
10. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-2580.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas and insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
12. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. J Am Coll Cardiol 2005; 46: 821-826.
13. Califf RM. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J 2003; 5: 13-18.
14. The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Trial Investigators. Rationale, design and recruitment characterization of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-1527.
15. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. the DREAM Trial Investigators. N Engl J Med 2006; 355: 1551-1562.
16. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23: 891-898.
17. Morel Y, Gadient A, Keller U, Vadas L, Golay A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995; 26: 306-311.
18. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
19. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin-converting enzyme inhibitor. Hypertension 1994; 23: 450-455.
20. Tom B, Dendorfer A, Danser AHJ. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol 2003; 35: 792-801.
21. Balon TW, Nadler JL. Evidence that nitric oxides increase glucose transport in skeletal muscle. J Appl Physiol 1997; 82: 359-363.
22. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin-resistant muscle. roles of bradykinin and nitric oxide. Am J Physiol 1999; 277: R332-R336.
23. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27: 1015.
24. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2005; 109: 2054-2057.
25. Leiter LA. β-cell preservation: a potential role for thiazolinediones to improve clinical care in Type 2 diabetes. Diabet Med 2005; 22: 963-972.
26. Juan CC, Chien Y, Wu LY, Yang WM, Chang CL, Lai YH et al. Angiotensin II enhances insulin sensitivity in vitro and in vivo. Endocrinology 2005; 146: 2246-2254.
27. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G et al. The adipose-tissue renin-angiotensin-aldosterone system: role in metabolic syndrome. Int J Biochem Cell Biol 2003; 35: 807-825.
28. Janke J, Engeli S, Gorzeliniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human pre-adipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-1707.
29. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.
30. Hellerstrom C. The life story of the pancreatic B cell. Diabetologia 1984; 26: 393-400.
31. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A et al. Predominant role of reduced β-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 2003; 46: 1211-1219.
32. Lavoie JL, Sigmund CD. Overview of the renin-angiotensin system: an endocrine and paracrine system. Endocrinology 2003; 144: 2179-2183.
33. Montgomery H, Humphries SE, Leung PS. Renin-angiotensin system: the new frontier. Int J Biochem Cell Biol 2003; 35: 758.
34. Leung PS. The peptide hormone angiotensin II: its new functions in tissues and organs. Curr Protein Pept Sci 2004; 5: 267-273.
35. Leung PS, Carlsson PO. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 2001; 26: 155-164.
36. Leung PS, Chappell MC. A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol 2003; 35: 838-846.
37. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-133.
38. Tsang SW, Cheng CHK, Leung PS. The role of pancreatic renin-angiotensin system in acinar digestive enzyme secretion and in acute pancreatitis. Regul Pept 2004; 119: 213-219.
39. Fink AS, Wang Y, Mendez T, Worrell RT, Eaton D, Nguyen TD et al. Angiotensin II evokes calcium-mediated signalling events in isolated dog pancreatic epithelial cells. Pancreas 2002; 25: 290-295.
40. Leung PS, Chan HC, Fu LXM, Wong PYD. Localization of AT1 and AT2 receptors in the pancreas of rodents. J Endocrinol 1997; 153: 269-274.
41. Leung PS, Chan WP, Wong TP, Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 1999; 160: 13-19.
42. Leung PS, Chan WP, Nobiling R. Regulated expression of pancreatic renin-angiotensin system in pancreatitis. Mol Cell Endocrinol 2000; 166: 121-128.
43. Ip SP, Kwan PC, Williams CH, Pang S, Hooper NM, Leung PS. Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis. Int J Biochem Cell Biol 2003; 35: 944-954.
44. Tsang SW, Ip SP, Wong TP, Che CT, Leung PS. Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis. Regul Pept 2003; 111: 47-53.
45. Ip SP, Tsang SW, Wong TP, Che CT, Leung PS. Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis. Pancreas 2003; 26: 224-229.
46. Tsang SW, Ip SP, Leung PS. Prophylactic and therapeutic treatments with AT1 and AT2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int J Biochem Cell Biol 2004; 36: 330-339.
47. 1 receptor antagonism ameliorates acute pancreatitis-associated pulmonary injury. Regul Pept 2006; 134: 46-53.
48. Wong PF, Lee SST, Cheung WT. Immunohistochemical colocalization of type II angiotensin receptors with somatostatin in rat pancreas. Regul Pept 2004; 117: 196-205.
49. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999; 161: 317-322.
50. Ramracheya RD, Muller DS, Wu Y, Whitehouse BJ, Huang GC, Amiel SA et al. Direct regulation of insulin secretion by angiotensin II in human islet of Langerhans. Diabetologia 2006; 49: 321-331.
51. Olsson R, Jansson L, Andersson A, Carlsson PO. Local blood flow regulation in transplanted rat pancreatic islets: influence of adenosine, angiotensin II and nitric oxide inhibition. Transplantation 2000; 70: 280-287.
52. Kampf C, Lau T, Olsson R, Leung PS, Carlsson PO. Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularized syngeneic mouse islet grafts. Diabetologia 2005; 48: 1159-1167.
53. Leung PS, Carlsson PO. Pancreatic islet renin-angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 2005; 30: 293-298.
54. Leung PS, Hayek A, De Gasparo M. Frontiers in diabetic research. Int J Biochem Cell Biol 2006; 38: 687-688.
55. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commum 2004; 316: 114-122.
56. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 1994; 24: S317-S320.
57. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-997.
58. 1 receptor blockade improves β-cell function and glucose tolerance in mouse model of type 2 diabetes. Diabetes 2006; 55: 367-374.
59. Chua SC, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271: 994-996.
60. Rincon-Choles H, Kasinath BS, Gorin Y, Abboud HE. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 2002; 82: 8-11.
61. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003; 35: 826-837.
62. Lupi R, Guerra SD, Bugliani M, Boggi U, Mosca F, Torri S et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 2006; 154: 355-361.
63. Ko SH, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY et al. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem 2006; 98: 343-355.